Blue Faery: The Adrienne Wilson Liver Cancer Association

09/08/2026

"Success isn't about winning awards. It's about seeing my patients live whole lives." Dr. Anjana Pillai, Medical Director at the University of Chicago, shares how her childhood in India shaped her approach to transplant oncology and treating the "intimidating" complexity of the liver.

Read her story: https://vist.ly/5hq3j

09/07/2026

Scientists Discover Potential New Cancer Treatment

By blocking this protein, the research team found that it may be possible to develop new treatments for specific cancers which hijack the body's growth system through this genetic error.

Bowel cancer remains the second most common cause of cancer death across the country, claiming around 1,700 lives annually.

While around 670 people die from liver cancer each year in Scotland so finding more effective ways to tackle the disease is vital.

Lead researcher on the project Prof Owen Sansom said: "Because NPM1 isn't essential for normal adult tissue health, blocking it could be a safe way to treat certain cancers, like some hard-to-treat bowel and liver cancers. https://vist.ly/5hk9v

The research focused on the genetic faults that allow the disease to hijack a signalling system in the body.

09/04/2026

HCC: LLM Advice and Treatment Concordance

Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma; however, greater disagreement with physician recommendations was seen in cases of late-stage disease, according to findings from a Korean retrospective registry study published in PLOS Medicine.

“Our study shows that [LLMs] can help support treatment decisions for early-stage liver cancer, but their performance is more limited in advanced disease. This highlights the importance of using LLMs as a complement to, rather than a replacement for, clinical expertise,” the study authors, including corresponding author Ji Won Han, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, wrote. 가톨릭대학교 The Catholic University of Korea https://vist.ly/5hbsr

Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma...

09/02/2026

Non-invasive Ultrasound Treatment for Liver Tumors Comes to Hackensack Meridian Jersey Shore University Medical Center

Patients with liver cancer or cancers that have spread to the liver will soon have an emerging, non-invasive option to consider at Hackensack Meridian Jersey Shore University Medical Center (JSUMC). The hospital is among only three in the state — and the only one in Monmouth and Ocean counties — that will offer the approach known as histotripsy, beginning in February. This innovative technology uses focused ultrasound waves to mechanically destroy tumors and cancerous tissue, turning them into liquid which the body naturally reabsorbs.

“This is one of the most fascinating technologies I’ve seen in my career,” said Gregory Tiesi, MD, FACS, FSSO, chief of surgical oncology at JSUMC. “Histotripsy uses a specialized device to focus ultrasound waves precisely on the targeted tumor, liquefying the tissue without damaging surrounding healthy structures. This precision allows us to preserve vital structures, without the risk of spreading cancer cells, and can be used in patients who might not otherwise have options like surgery.” Hackensack Meridian Health https://vist.ly/5g2nh

Available for cancerous and benign tumors; women who take oral contraceptives long term are at a 30% to 40% increase risk in developing benign liver tumors (ie. HCAs), which impact liver health

09/01/2026

Starting conversations about liver cancer – whether with family, friends, or a doctor – can feel challenging.
That's why it can be helpful to have tools that help you organize your thoughts and feel better prepared for essential discussions. Eisai US
The One Liver to Love website features conversation cards available in multiple languages that may help: https://vist.ly/5gvu4.

08/31/2026

AI Treatment Suggestions for Liver Cancer More Accurate at Early Stages

An artificial intelligence (AI)-based large language model (LLM) was able to match clinician suggestions for simple, early stage hepatocellular carcinoma but was less able to match clinical recommendations for more complex, later stage cases.

As reported in PLOS Medicine, for the earlier stage cases the treatment suggested by the LLM was linked to better survival, but for late stage cases the closer the treatment matched the AI suggestion the poorer the patient’s outcome was.

“Liver cancer… is common worldwide, and choosing the right treatment can be difficult because it depends on both the cancer stage and how well the liver is functioning,” write lead author Ji Won Han, a researcher based at the Catholic University of Korea, and colleagues. 가톨릭대학교 The Catholic University of Korea https://vist.ly/5grmc

A large Korean study shows AI-based treatment suggestions are most effective in simple, earlier stage hepatocellular carcinoma cases.

08/28/2026

Atezolizumab Combo May Be Superior to TACE for Certain Liver Cancers

Atezolizumab plus bevacizumab demonstrated a longer time to failure of treatment strategy (TTFS) than transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

The results were based on the first interim analysis of the phase 3b ABC-HCC trial presented at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco (Abstract 478).

“This is the first interim analysis of the comparison of systemic therapy with atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage disease,” said lead author Peter R. Galle, MD, from University Medical Center Mainz in Germany. “The time to failure of treatment strategy endpoint is prolonged in patients receiving systemic therapy, suggesting superiority of systemic therapy compared to TACE.” American Society of Clinical Oncology Universitätsmedizin Mainz https://vist.ly/5ghcs

Atezolizumab plus bevacizumab demonstrated a longer time to failure of treatment strategy than transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma, according to early data from the phase 3b ABC-HCC trial presented at the 2026 ASCO Gastrointestinal Cancers Sym...

08/27/2026

August may be ending, but the need for hope, education, and support continues every day. Members of 𝗕𝗹𝘂𝗲 𝗙𝗮𝗲𝗿𝘆'𝘀 𝗦𝘂𝗺𝗺𝗲𝗿𝗹𝗮𝗻𝗱 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗲𝗿 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 provide reliable monthly support that helps patient resources, educational programs, and advocacy remain available throughout the year.

Learn how steady giving creates lasting impact: https://vist.ly/5gd6r

08/26/2026

A Natural “Safety Switch” Protects the Liver as it Heals from Injury, Study Finds

New research from scientists at Fox Chase Cancer Center has uncovered a natural “safety switch” in the liver that helps prevent cancer from developing while the organ repairs itself after injury.

The study, published in Nature Communications, shows that liver cells can temporarily pause their growth during times of stress, reducing the risk that rapid regeneration could turn into cancer. The findings shed new light on how the liver balances healing with long-term protection against liver cancer.

“This research gives us a clearer picture of how the liver protects itself. Understanding that process may help us design safer, more effective treatments for liver disease,” said Joan Font-Burgada, PhD, senior author on the paper and an Assistant Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase. Fox Chase Cancer Center https://vist.ly/5g8tn

08/25/2026

Clinical trials can offer patients access to new approaches being studied in liver cancer care—but figuring out where to begin can feel overwhelming.

Blue Faery's 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 𝗽𝗮𝗴𝗲 brings current featured opportunities together in one place and provides resources to help patients and caregivers explore possible options.

If you or someone you love is living with liver cancer, take a look at the trials currently listed and use the resource on the page to search for studies that may be a match. Then, talk with your healthcare team about whether a clinical trial could be appropriate for you.

Explore liver cancer clinical trials: https://vist.ly/5g4vk